IL136250A0 - Metabotropic glutamate receptor antagonist compounds - Google Patents
Metabotropic glutamate receptor antagonist compoundsInfo
- Publication number
- IL136250A0 IL136250A0 IL13625098A IL13625098A IL136250A0 IL 136250 A0 IL136250 A0 IL 136250A0 IL 13625098 A IL13625098 A IL 13625098A IL 13625098 A IL13625098 A IL 13625098A IL 136250 A0 IL136250 A0 IL 136250A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor antagonist
- glutamate receptor
- metabotropic glutamate
- antagonist compounds
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6675897P | 1997-11-21 | 1997-11-21 | |
PCT/US1998/024833 WO1999026927A2 (en) | 1997-11-21 | 1998-11-20 | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
IL136250A0 true IL136250A0 (en) | 2001-05-20 |
Family
ID=22071510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13625098A IL136250A0 (en) | 1997-11-21 | 1998-11-20 | Metabotropic glutamate receptor antagonist compounds |
IL136250A IL136250A (en) | 1997-11-21 | 2000-05-21 | Metabotropic glutamate receptor antagonist compounds |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL136250A IL136250A (en) | 1997-11-21 | 2000-05-21 | Metabotropic glutamate receptor antagonist compounds |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1037878A2 (en) |
JP (1) | JP2001524468A (en) |
CN (2) | CN1158264C (en) |
AU (2) | AU771358B2 (en) |
CA (1) | CA2311131A1 (en) |
IL (2) | IL136250A0 (en) |
MX (1) | MXPA00004940A (en) |
NZ (1) | NZ505207A (en) |
WO (1) | WO1999026927A2 (en) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2642699A (en) * | 1998-03-03 | 1999-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Remedies for brain infarction |
GB9823845D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
GB9823847D0 (en) * | 1998-11-02 | 1998-12-23 | Lilly Co Eli | Pharmaceutical compounds |
DE60022050C5 (en) * | 1999-06-02 | 2007-10-11 | NPS Pharmaceuticals, Inc., Salt Lake City | METABOTROPE GLUTAMATE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
AU6420700A (en) * | 1999-08-05 | 2001-03-05 | Prescient Neuropharma Inc. | Novel 1,4-benzodiazepine compounds and derivatives thereof |
EP1582519A3 (en) * | 1999-08-19 | 2005-12-21 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
BR0013427A (en) * | 1999-08-19 | 2002-07-30 | Nps Pharma Inc | Heteropolyclic Compounds and Their Uses as Metabotropic Glutamate Receptor Antagonists |
US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
SI1224174T1 (en) * | 1999-10-15 | 2003-12-31 | F. Hoffmann-La Roche Ag | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists |
CN1199954C (en) | 1999-10-15 | 2005-05-04 | 弗·哈夫曼-拉罗切有限公司 | Benzodiazepine derivatives |
GB0007193D0 (en) * | 2000-03-25 | 2000-05-17 | Univ Manchester | Treatment of movrmrnt disorders |
MXPA03002907A (en) * | 2000-10-02 | 2003-06-24 | Janssen Pharmaceutica Nv | Metabotropic glutamate receptor antagonists . |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
US20060100196A1 (en) * | 2001-09-24 | 2006-05-11 | Andrea Gailunas | Substituted amines for the treatment of alzheimer's disease |
MXPA04009435A (en) * | 2002-03-29 | 2005-01-25 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands. |
CN100357283C (en) * | 2002-04-02 | 2007-12-26 | 中国科学院上海药物研究所 | Methionyl aminopeptidase inhibitor |
AR040847A1 (en) | 2002-08-09 | 2005-04-20 | Astrazeneca Ab | 1,2,4-OXADIAZOLES AS METABOTROPIC GLUTAMATE RECEPTORS MODULATORS, FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
CA2513824A1 (en) * | 2003-01-31 | 2004-08-19 | Astrazeneca Ab | Saturated quinoxaline derivatives and their use as metabotropic glutamate receptor ligands |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
WO2005041684A2 (en) | 2003-08-06 | 2005-05-12 | Senomyx Inc. | Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof |
SE0302192D0 (en) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
US7501416B2 (en) | 2004-02-06 | 2009-03-10 | Bristol-Myers Squibb Company | Quinoxaline compounds and methods of using them |
US9012494B2 (en) | 2004-05-07 | 2015-04-21 | Janssen Pharmaceutica N.V. | Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
NZ553159A (en) * | 2004-08-30 | 2010-05-28 | Janssen Pharmaceutica Nv | N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
DE602005017159D1 (en) | 2004-08-30 | 2009-11-26 | Janssen Pharmaceutica Nv | OXYSTEROID DEHYDROGENASE INHIBITORS |
RU2386617C2 (en) | 2004-08-30 | 2010-04-20 | Янссен Фармацевтика Н.В. | TRICYCLIC LACTAM DERIVATIVES AS 11-β-HYDROXYSTEROID DEHYDROGENASE INHIBITORS |
WO2006084186A2 (en) | 2005-02-04 | 2006-08-10 | Senomyx, Inc. | Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
CN101160285A (en) | 2005-03-17 | 2008-04-09 | 辉瑞大药厂 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists |
GB0506133D0 (en) * | 2005-03-24 | 2005-05-04 | Sterix Ltd | Compound |
AR055329A1 (en) | 2005-06-15 | 2007-08-15 | Senomyx Inc | BIS-AROMATIC AMIDAS AND ITS USES AS SWEET FLAVORS, FLAVORS, AND FLAVOR ENHANCERS |
MX2007015863A (en) * | 2005-06-17 | 2008-04-02 | Apogee Biotechnology Corp | Sphingosine kinase inhibitors. |
US7868008B2 (en) | 2005-08-12 | 2011-01-11 | Astrazeneca Ab | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
EP1912940A1 (en) * | 2005-08-12 | 2008-04-23 | AstraZeneca AB | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
WO2007037543A1 (en) * | 2005-09-29 | 2007-04-05 | Banyu Pharmaceutical Co., Ltd. | Biarylamide derivative |
EP1957475A1 (en) * | 2005-10-21 | 2008-08-20 | Merz Pharma GmbH & Co.KGaA | Chromenones and their use as modulators of metabotropic glutamate receptors |
US20090005363A1 (en) * | 2005-12-20 | 2009-01-01 | Ralf Glatthar | Organic Compounds |
TW200804281A (en) | 2006-02-16 | 2008-01-16 | Astrazeneca Ab | New metabotropic glutamate receptor-potentiating isoindolones |
ES2640453T3 (en) | 2006-04-21 | 2017-11-03 | Senomyx, Inc. | Processes for preparing solid flavoring compositions |
TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
RU2450004C2 (en) | 2006-08-04 | 2012-05-10 | Мерц Фарма Гмбх Унд Ко. Кгаа | Substituted pyrazolopyrimidines, method for preparing and using them as drug |
CA2669915C (en) | 2006-11-17 | 2012-02-07 | Pfizer Inc. | Substituted bicyclocarboxyamide compounds |
EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
JP2010522227A (en) | 2007-03-22 | 2010-07-01 | アストラゼネカ・アクチエボラーグ | Quinoline derivatives for the treatment of inflammatory diseases |
EP2137167B1 (en) | 2007-04-19 | 2011-08-10 | F. Hoffmann-La Roche AG | Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives |
TWI417100B (en) | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 |
CN101348461B (en) * | 2007-07-17 | 2011-10-05 | 西安利君制药有限责任公司 | N-(3-pyridine formyloxy)-3,5-dimethyl-1-amantadine for curing senile dementia or pharmaceutical salt thereof |
EP2064959B1 (en) | 2007-10-31 | 2012-07-25 | Symrise AG | Aromatic Neomenthylamides as flavouring agents |
PE20091036A1 (en) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR |
US8211882B2 (en) * | 2008-03-08 | 2012-07-03 | Richard Delarey Wood | Glutamate receptor modulators and therapeutic agents |
SA109300358B1 (en) | 2008-06-06 | 2012-11-03 | استرازينيكا ايه بي | Isoindolone Metabotropic Glutamate receptor Potentiators |
US8415333B2 (en) | 2009-02-24 | 2013-04-09 | Respiratorious Ab | Bronchodilating diazaheteroaryls |
WO2011109398A2 (en) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
WO2011150380A1 (en) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
WO2012006760A1 (en) * | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Tricyclic compounds as allosteric modulators of metabotropic glutamate receptors |
WO2012009646A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
EA023763B1 (en) * | 2010-11-30 | 2016-07-29 | Байер Интеллектчуал Проперти Гмбх | Pyrimidine derivatives and use thereof as pesticides |
KR102529578B1 (en) * | 2014-08-29 | 2023-05-09 | (주)아모레퍼시픽 | Novel adamatan derivative compound |
CN114539170B (en) * | 2021-12-31 | 2023-05-16 | 华南农业大学 | Hapten and artificial antigen for simultaneously detecting amantadine, olaquindox and chloramphenicol, and preparation method and application thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632581A (en) * | 1968-10-08 | 1972-01-04 | American Home Prod | Schiff bases of quinoxaline-2-carboxal-dehydes and their reduction products |
GB1329447A (en) * | 1969-10-27 | 1973-09-05 | Squibb & Sons Inc | 4-adamantylaminoalkylamino-2-styryl-quinolines salts and derivatives thereof |
FR2355829A1 (en) * | 1976-06-24 | 1978-01-20 | Debat Lab | Esters of nitroxoline with (poly)carboxylic or (poly)sulphonic acids - useful as antibacterials and antifungals |
IL53440A0 (en) * | 1977-11-22 | 1978-01-31 | Teva Pharma | 2-adamantyl hydrazines their preparation and pharmaceutical compositions containing them |
FR2509728A1 (en) * | 1981-07-17 | 1983-01-21 | Roussel Uclaf | NOVEL QUINOLINE DERIVATIVES, THEIR SALTS, PREPARATION METHOD, MEDICAMENT APPLICATION AND COMPOSITIONS COMPRISING THE SAME |
US5346907A (en) * | 1988-04-05 | 1994-09-13 | Abbott Laboratories | Amino acid analog CCK antagonists |
IE902295A1 (en) * | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
EP0669321B1 (en) * | 1989-07-07 | 2000-09-27 | Meiji Seika Kabushiki Kaisha | Use of 4-acyloxyquinoline derivatives as insecticides or acaricides |
WO1991014677A1 (en) * | 1990-03-28 | 1991-10-03 | Otsuka Pharmaceutical Co., Ltd. | Quinoline derivative, antiulcer drug containing the same, and production of said derivative |
JPH0441425A (en) * | 1990-06-07 | 1992-02-12 | Tanabe Seiyaku Co Ltd | 5-lipoxygenase inhibitor |
WO1994001408A1 (en) * | 1992-07-10 | 1994-01-20 | Laboratoires Glaxo S.A. | Anilide derivatives |
JPH07179371A (en) * | 1993-12-21 | 1995-07-18 | Canon Inc | Liquid crystal compound, liquid crystal composition containing the compound, liquid crystal element using the composition, displaying method and displaying apparatus using the element |
US5716944A (en) * | 1994-07-04 | 1998-02-10 | Takeda Chemical Industries, Ltd. | Phosphonic acid compounds, their production and use |
WO1996005818A1 (en) * | 1994-08-19 | 1996-02-29 | Nps Pharmaceuticals, Inc. | Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases |
US5707985A (en) * | 1995-06-07 | 1998-01-13 | Tanabe Seiyaku Co. Ltd. | Naphthyl-, quinolyl- and isoquinolyl- sulfonamide derivatives as cell adhesion modulators |
TR199902724T2 (en) * | 1997-05-03 | 2000-04-21 | Smithkline Beecham P.L.C. | Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors. |
-
1998
- 1998-11-20 CN CNB98813148XA patent/CN1158264C/en not_active Expired - Fee Related
- 1998-11-20 AU AU15317/99A patent/AU771358B2/en not_active Ceased
- 1998-11-20 CA CA002311131A patent/CA2311131A1/en not_active Abandoned
- 1998-11-20 MX MXPA00004940A patent/MXPA00004940A/en active IP Right Grant
- 1998-11-20 CN CNA2004100474998A patent/CN1554649A/en active Pending
- 1998-11-20 WO PCT/US1998/024833 patent/WO1999026927A2/en active Application Filing
- 1998-11-20 EP EP98959535A patent/EP1037878A2/en not_active Withdrawn
- 1998-11-20 JP JP2000522085A patent/JP2001524468A/en active Pending
- 1998-11-20 IL IL13625098A patent/IL136250A0/en not_active IP Right Cessation
- 1998-11-20 NZ NZ505207A patent/NZ505207A/en unknown
-
2000
- 2000-05-21 IL IL136250A patent/IL136250A/en unknown
-
2004
- 2004-06-17 AU AU2004202776A patent/AU2004202776B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU771358B2 (en) | 2004-03-18 |
CN1285820A (en) | 2001-02-28 |
WO1999026927A3 (en) | 1999-10-21 |
NZ505207A (en) | 2003-10-31 |
AU2004202776A2 (en) | 2004-07-22 |
AU2004202776A1 (en) | 2004-07-22 |
EP1037878A2 (en) | 2000-09-27 |
WO1999026927A2 (en) | 1999-06-03 |
CN1158264C (en) | 2004-07-21 |
JP2001524468A (en) | 2001-12-04 |
AU1531799A (en) | 1999-06-15 |
MXPA00004940A (en) | 2002-10-17 |
CN1554649A (en) | 2004-12-15 |
AU2004202776B2 (en) | 2008-06-19 |
CA2311131A1 (en) | 1999-06-03 |
IL136250A (en) | 2006-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL136250A0 (en) | Metabotropic glutamate receptor antagonist compounds | |
PL357433A1 (en) | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists | |
AU4797400A (en) | Metabotropic glutamate receptor antagonists | |
PL357418A1 (en) | Benzodiazepine derivatives as metabotropic glutamate receptor antagonists | |
AU7079498A (en) | Neuropeptide y receptor antagonist | |
IL155163A0 (en) | Metabotropic glutamate receptor antagonists | |
IL133235A0 (en) | 1-Amino-alkylcyclohexane nmda receptor antagonists | |
AU6144098A (en) | Amide derivatives as selective neuropeptide y receptor antagonists | |
HU9601529D0 (en) | Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists | |
EP1000031A4 (en) | Vitronectin receptor antagonist | |
HU9801861D0 (en) | Ccr-3 receptor antagonists | |
ZA951345B (en) | Adhesion receptor antagonist | |
IL135797A0 (en) | Thrombin receptor antagonists | |
IL135189A0 (en) | Vitronectin receptor antagonist | |
IL135188A0 (en) | Vitronectin receptor antagonist | |
EP1226164A4 (en) | Human metabotropic glutamate receptor | |
IL134301A0 (en) | 2-acylaminopropanamines as tachykinin receptor antagonists | |
AU1296899A (en) | Phenyl-alkyl-imidazoles as h3 receptor antagonists | |
EP0912182A4 (en) | Fibrinogen receptor antagonist prodrugs | |
EP1023295A4 (en) | Fibrinogen receptor antagonist prodrugs | |
IL134155A0 (en) | 2-acylaminopropanamines as tachykinin receptor antagonists | |
AU6826498A (en) | Endotholin receptor antagonists | |
EP1131335A4 (en) | 7tm receptor hlwar77 | |
HU9400706D0 (en) | Benzylimidazopyridine derivative as angiotensin ii receptor antagonist | |
AU1150999A (en) | Indole derivative useful as endothelin receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |